|
|||||
|
|
Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy |
|
| Authors: | Kristina S Boye Katie D Stewart Jessica Jordan Giovanni Biricolti Silvia Del Santo |
| Institution: | 1. Eli Lilly and Company, Indianapolis, IN, USA;2. Evidera, Bethesda, MD, USA;3. Eli Lilly Italia S.p.A, Sesto Fiorentino, Italy |
| Abstract: | |
| Keywords: | Utility time trade-off injection device dulaglutide semaglutide patient preference Italy |